AP NEWS
Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against TG Therapeutics, Inc.

November 22, 2018 GMT

BENSALEM, Pa.--(BUSINESS WIRE)--Nov 21, 2018--Law Offices of Howard G. Smith reminds investors of the December 3, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX ) securities between  June 4, 2018 and September 25, 2018,   inclusive (the “Class Period”). TG Therapeutics investors have until  December 3, 2018 to file a lead plaintiff motion.

Investors suffering losses on their TG Therapeutics investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On September 26, 2018, TG Therapeutics announced that it could not proceed with the interim analysis of one of its leading product candidates, Ublituximab (TG-1101), following a determination by the FDA Data Safety Monitoring Board trials that the UNITY-CLL trial data was not mature enough to continue. On this news, TG Therapeutics dropped 44% to close at $5.15 per share, thereby injuring investors.

The complaint filed in this class action alleges that the Company made false and misleading statements to the market. TG Therapeutics was engaged in cleaning the data collected from its UNITY-CLL study, which gave it an understanding of the efficacy of the combination therapy. Based on that understanding, the Company knew the study had failed to reach its goals, and therefore knew it would not be able to seek accelerated approval. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period.

If you purchased shares of TG Therapeutics during the Class Period you may move the Court no later than  December 3, 2018 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at 215-638-4847, toll-free at 888-638-4847, or by email to  howardsmith@howardsmithlaw.com, or visit our website at  http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181121005570/en/

CONTACT: Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

888-638-4847

howardsmith@howardsmithlaw.com

www.howardsmithlaw.com

KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA

INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL

SOURCE: Law Offices of Howard G. Smith

Copyright Business Wire 2018.

PUB: 11/21/2018 07:00 PM/DISC: 11/21/2018 07:00 PM

http://www.businesswire.com/news/home/20181121005570/en